UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,926	07/22/2005	Heinz Berner	IB/G-32577A/ABR 9926	6141
	7590 01/08/200 CHBERG CO. L.P.A.	EXAMINER		
1940 EAST 6TI	H STREET		COVINGTON, RAYMOND K	
CLEVELAND, OH 44114			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			01/08/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Office Action Comments	10/521,926	BERNER ET AL.
Office Action Summary	Examiner	Art Unit
	Raymond Covington	1625
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR RE WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	B DATE OF THIS COMMUNICA R 1.136(a). In no event, however, may a repriod will apply and will expire SIX (6) MONTH atute, cause the application to become ABAI	ATION. y be timely filed IS from the mailing date of this communication. IDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on <u>02</u>	his action is non-final. wance except for formal matter	•
Disposition of Claims		
4) ☐ Claim(s) 1-5,7,8 and 10 is/are pending in the 4a) Of the above claim(s) is/are without 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-5,7,8 and 10 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	drawn from consideration.	
Application Papers		
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the cor 11) The oath or declaration is objected to by the	accepted or b) objected to by the drawing(s) be held in abeyance rection is required if the drawing(s)	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority document of: 2. Certified copies of the priority document of the priority documen	ents have been received. ents have been received in Apportiority documents have been re reau (PCT Rule 17.2(a)).	olication No eceived in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/l	nmary (PTO-413) Mail Date rmal Patent Application

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1-5, 7, 8 and 10 are again rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is not clear what is meant by the phrase "the residue of an amino acid".

Does the fragment include amine, carboxylic acid, esters, alcohols even hydrogen.

Applicants' Have been noted and considered but are not deemed persuasive of patentability. Even as amended it is still not clear what this phrase means and how it would not read on the prior art.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-5, 7, 8 and 10 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Ascher et al US 769804 and/or Berry et al US RE39128.

Ascher et al and Berry et al teach antibacterial mutilin compounds and compositions corresponding to those recited in the claims. See, for example, column 1 line 1 to column 2 line 34 of Ascher et al and column 2 lines 2-52, column 3 lines 5-10 and examples 10, 15 and 37 of Berry et al.

While the alkyls on the corresponding R_5 substituent may differ in number, such differences in closely structurally related compounds would have been obvious to one of ordinary skill in the art as the resulting products would not have been unexpected.

Regarding applicants' comments it is noted that the claims as presently amended still read on the prior art where the residue of an amino acid corresponding to applicants' R_5 is, e.g. -(C=O)-alkyl. It is noted that this particular residue of an amino acid is also bound to nitrogen of the N-ring and is missing the -OH group.

Regarding applicants' additional comments regarding data, it is noted that it are not in proper affidavit form, does not show whether the closest prior art was compared nor a nexus to the claimed utility and as such not considered probative to the method claim 10.

Art Unit: 1625

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond Covington whose telephone number is (571) 272-0681. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres at telephone number (571) 272-0867.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/R. C./ Examiner, Art Unit 1625 /Janet L. Andres/ Supervisory Patent Examiner, Art Unit 1625

RKC